Q-omics provides the consensus-scored CCDC70 profile across patient tissues and cancer cell-line models. CCDC70 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CCDC70 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, CCDC70 protein abundance shows 24,210 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight DLBC, BRCA, and GBM as cancer lineages where CCDC70 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC70 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC70 survival associations across molecular data types. CCDC70 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC70 RNA expression–survival associations across cancer types. High CCDC70 expression shows unfavorable associations in DLBC, SCLC, LUAD, THCA, THYM and READ. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify DLBC as the clearest survival context for CCDC70 RNA expression.
This table summarizes CCDC70 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 5. The strongest signals are observed in BRCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC70. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC70 shows higher tumor expression in BRCA, STAD, COAD and KICH. The BRCA box plot shows higher CCDC70 RNA expression in tumor versus normal tissue (log2 FC = +0.049, t-test p = .003).
This table shows molecular features associated with CCDC70 in patient tissues and cancer cell lines. In patient samples, CCDC70 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC70 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
